You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-DA-23-021: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44- Clinical Trial Optional)

    Release Date: 03-28-2022Open Date: 07-15-2022 Due Dates: Multiple Close Date: 02-14-2025

    According to the Centers for Disease Control and Prevention (CDC), more than 100,000 deaths from overdose were reported from April 2020 to April 2021 alone. Data shows an increase in overdoses due to natural and semi-synthetic opioids, synthetic opioids, predominantly fentanyl, and psychostimulants, such as methamphetamine or cocaine. In fact, in the year ending in April 2021, fentanyl was the lea ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. PAR-22-102: Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)

    Release Date: 01-21-2022Open Date: 02-28-2022 Due Dates: Multiple Close Date: 12-05-2024

    Background Currently, there are only three medications (four formulations) approved by the FDA for the treatment of alcohol use disorder (AUD). The need for additional medications to treat those affected by AUD is urgently needed.In addition,alcohol misuseaffects virtually all tissues and is linked with dysfunction and failure of many organs and systems including the liver, heart, pancreas, lung, ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-HL-23-008: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

    Release Date: 11-16-2021Open Date: 01-28-2022 Due Dates: Multiple Close Date: 02-29-2024

    Since its inception in 1982, the NIH SBIR program has provided the small business community with seed funding to support the development of a broad array of commercial products to detect, diagnose, treat, and prevent disease.? It provides an important funding mechanism for bringing new interventions to patients and clinicians. The SBIR program is structured in three phases. The objective in Phase ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-HL-23-009: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

    Release Date: 11-16-2021Open Date: 01-28-2022 Due Dates: Multiple Close Date: 02-29-2024

    Since its inception in 1982, the NIH SBIR program has provided the small business community with seed funding to support the development of a broad array of commercial products to detect, diagnose, treat, and prevent disease. It provides an important funding mechanism for bringing new interventions to patients and clinicians. The SBIR program is structured in three phases. The objective in Phase I ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. RFA-CA-22-017: Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)

    Release Date: 03-21-2022Open Date: 07-22-2022Due Date: 08-22-2022Close Date: 08-23-2022

    Purpose Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI), National Institute of Biomedical Imaging and Bioengineering (NIBIB), and National Institute on Drug Abuse (NIDA) intend to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small bu ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. RFA-CA-22-025: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

    Release Date: 04-05-2022Open Date: 07-05-2022Due Date: 08-05-2022Close Date: 08-05-2022

    Purpose The Small Business Innovation Research (SBIR) Program is an important mechanism by which the National Institutes of Health (NIH) and other Federal agencies help bring innovative solutions to public health challenges. A major objective of the Federal SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of medi ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. RFA-ES-22-004: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)

    Release Date: 04-26-2022Open Date: 06-20-2022Due Date: 07-20-2022Close Date: 07-21-2022

    This SBIR Funding Opportunity Announcement (FOA) focuses on the development of e-Learning health and safety training products from a variety of delivery methods to assist both students and instructors in the training and education process. Note that all products must be directly related to the health and safety training of workers exposed to hazardous materials (HAZMAT). Workers that may be expose ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. AF222-0001: Hyperspectral, Wide Field of View Spatially Variant Photonic Crystals

    Release Date: 04-20-2022Open Date: 05-18-2022Due Date: 06-15-2022Close Date: 06-15-2022

    OUSD (R&E) MODERNIZATION PRIORITY: Microelectronics; General Warfighting Requirements (GWR) TECHNOLOGY AREA(S): Sensors; Electronics; Materials The technology within this topic is restricted under the International Traffic in Arms Regulation (ITAR), 22 CFR Parts 120-130, which controls the export and import of defense-related material and services, including export of sensitive technical d ...

    SBIRPhase I/Phase IIDepartment of DefenseAir Force
  9. AF222-0002: Automated Data Forensics for Collaborative Weapon Behaviors

    Release Date: 04-20-2022Open Date: 05-18-2022Due Date: 06-15-2022Close Date: 06-15-2022

    OUSD (R&E) MODERNIZATION PRIORITY: Autonomy; Artificial Intelligence/Machine Learning TECHNOLOGY AREA(S): Information Systems; Battlespace The technology within this topic is restricted under the International Traffic in Arms Regulation (ITAR), 22 CFR Parts 120-130, which controls the export and import of defense-related material and services, including export of sensitive technical data, ...

    SBIRPhase I/Phase IIDepartment of DefenseAir Force
  10. AF222-0003: Cloud-based IoT Acceptance Test Methodologies for Air Force Systems Integration

    Release Date: 04-20-2022Open Date: 05-18-2022Due Date: 06-15-2022Close Date: 06-15-2022

    OUSD (R&E) MODERNIZATION PRIORITY: Cybersecurity; Network Command, Control and Communications; Autonomy; Artificial Intelligence/Machine Learning; 5G TECHNOLOGY AREA(S): Sensors; Information Systems OBJECTIVE: Develop an automated Internet-of-Things Testing as a Service (IoT-TaaS) approach for assuring the resiliency and readiness of Air Force systems with embedded IoT technology. DESC ...

    SBIRPhase I/Phase IIDepartment of DefenseAir Force
US Flag An Official Website of the United States Government